Virtual Library
Start Your Search
Abhirup Chanda
Author of
-
+
P30 - Palliative and Supportive Care (ID 163)
- Event: WCLC 2020
- Type: Posters
- Track: Palliative and Supportive Care
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P30.06 - Outcome Differences Amongst Histopathological Variants of Non Small Cell Lung Cancer Treated With Palliative Radiotherapy (ID 3633)
00:00 - 00:00 | Presenting Author(s): Abhirup Chanda
- Abstract
Introduction
Squamous cell carcinoma and adenocarcinoma are the two major histopathological subtypes of non small cell lung cancer. Amongst these, Squamous Cell subtype is predominant in India. Thoracic palliative radiation therapy offers symptomatic relief to patients with distressing symptoms caused out of loco-regionally advanced disease. But the overall outcome of patients are often dependent upon intrinsic tumor biology and histopathological subtypes, apart from other relevant patient related characteristics.
Methods
Between August 2018 and January 2020, newly diagnosed 48 patients of histopathologically proven non small cell lung carcinoma, presenting with thoracic distressing symptoms were included in this single armed, single institutional, prospective, observational study, after seeking informed consent from all, out of whom 36 patients had squamous cell carcinoma, while rest 12 had adenocarcinoma. Patients of stage IIIB to IVB, with ECOG performance status 2-3, requiring palliative radiation therapy for relief of local thoracic symptoms were included. All patients were treated with 30 Gy, divided in 10 fractions (3 Gy per fraction), over 2 weeks time (5 days in a week). Treatment response was assessed after 6 weeks of completion of radiation therapy by contrast enhanced CT scan of thorax in accordance with RECIST 1.1 criteria. Patients with partial response and stable disease were considered as treatment responders (having local control) while patients with progressive disease were taken as treatment non-responders. Patients were followed up via phone calls to the patients themselves or to their family members. Survival period was recorded as starting from the time of histopathological diagnosis to the date of death or termination of the study (June 2020).
Results
Distribution of patients with two major histopathological subtypes of non small cell lung cancer in accordance with treatment response at 6 weeks post palliative radiation therapy Histopathological subtypes Partial Response Stable Disease Progressive Disease Squamous Cell Carcinoma (n=36)
12 (33.33%) 10 (27.78%) 14 (38.89%) Adenocarcinoma (n=12) 2 (16.67%) 8 (66.67%) 2 (16.67%) Adenocarcinoma variant responded more to radiation therapy as compared to squamous cell carcinoma in terms of local control (Treatment responders; adenocarcinoma vs squamous cell carcinoma : 83.33% vs 61.11%), though more percentage of patients with squamous cell carcinoma had partial response.
Median overall survival (OS) of all 48 patients were 5.85 months. Patients with adenocarcinoma experienced better survival than that of squamous cell carcinoma (Median overall survival; adenocarcinoma vs squamous cell carcinoma : 11.35 vs 4.95 months) after palliative radiation therapy.
Conclusion
Adenocarcinoma subtype of non small cell lung cancer tend to have better objective response after palliative thoracic radiotherapy in advanced stage diseases along with better overall survival as compared to squamous cell carcinoma.
-
+
P37 - Pathology - Biomarker Testing (ID 107)
- Event: WCLC 2020
- Type: Posters
- Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P37.11 - Assessment of Plasma D-Dimer as a Predictive Biomarker for Treatment Response in Lung Cancer Treated with Radiation Therapy (ID 3307)
00:00 - 00:00 | Presenting Author(s): Abhirup Chanda
- Abstract
Introduction
Plasma D-dimer, a sensitive biomarker for fibrinolysis in human body, is found raised in lung cancer patients. Increased D-dimer level is associated with large malignant tumor burden and poor clinical progression, hence changes in its concentration post treatment can be an indirect measure of changes in tumor burden, thus predicting treatment response. Treatment response assessment criteria are generally set upon radiological evidence of change in tumor volume. Radiation therapy to thorax causes regression of malignant lung tumor but with variable degree of surrounding fibrosis. This fibrosed tissue may obscure the actual volume of residual tumor (if any), thus giving false estimation of treatment response. A sensitive tumor biomarker may help to corroborate the findings of radiological imaging based response assessment.
Methods
Between August 2018 and February 2020, previously untreated, histopathologically proven, fifty patients of locally advanced (stage IIIB, IIIC) and advanced (stage IV) non small cell lung cancer, presenting with pressing local symptoms, were included in this prospective, observational, single institutional study, after seeking informed consent. Pre treatment plasma D-dimer estimation was done in every patient before initiation of treatment with hypofractionated radiation therapy with 30 Gy, divided in 10 fractions (3 Gy per fraction), over a period of 10 days (5days in a week). Plasma D-dimer level of 0 to 500 ng/ml was considered normal. Treatment response was evaluated at 6 weeks after radiotherapy completion, by contrast enhanced CT scan of thorax and repeat plasma D-dimer evaluation was done at the same time. The correlation between pre and post treatment plasma D-dimer with respect to treatment response was evaluated by Wilcoxon Signed Rank Test, using IBM SPSS Statistics v26 software. P value < 0.05 was considered statistically signifiant.
Results
The median overall pre and post treatment plasma D-dimer levels were 1000 ng/ml (198 to 4800 ng/ml) and 1195 ng/ml (30 to 5694 ng/ml) respectively.
Majority of patients having partial response (10 out of 14; 71.43%) had decrement in D-dimer levels post treatment with radiation therapy and these changes were found statistically significant (P = 0.023; pre RT vs post RT median D-dimer : 1021 ng/ml [200 to 3051 ng/ml] vs 490.5 ng/ml [30 to 2680 ng/ml]).
Eleven out of 20 patients (55%) with stable disease had decrement in post treatment D-dimer levels, while the rest 9 patients (45%) with stable disease had further increment. Overall, these changes were not statistically significant (P = 0.661; pre RT vs post RT median D-dimer : 1062 ng/ml [305 to 4800 ng/ml] vs 1305.5 ng/ml [45 to 5694 ng/ml]).
However, most of the patients having progressive disease (15 out of 16; 93.75%) had increment in their plasma D-dimer levels post treatment with a statistical significant change (P = 0.001; pre RT vs post RT median D-dimer : 827.5 ng/ml [198 to 2690 ng/ml] vs 2130 ng/ml [152 to 3412 ng/ml]).
Conclusion
Plasma D-dimer possesses reasonably high prediction quotient for treatment response evaluation in lung cancer patients and may be used as a valuable, inexpensive biomarker to predict treatment response along with radiological imaging based response assessment.
